10th March, 2023 (Friday) |
||
Pre-congress: Industry Sponsored Dinner Symposium: Jansen
Chairperson: Tho Lye Mun |
||
Time | Topic | Speaker |
18.00-18.15 | Registration | |
18.15-18.20 | Welcoming speech | Lim Yee Pin |
18.20-18.25 | Opening remark | Tho Lye Mun |
18.25-18.45 | The knowns unknowns | John Low Seng Hooi |
18.45-19.15 | The new weapon | Cho Byoung Chul (Korea) |
19.15-20.00 | Case study & panel discussion | Tho Lye Mun
Panellists: Cho Byoung Chul (Korea) Liam Chong Kin Adlinda binti Alip Pathmanathan Rajadurai John Low Seng Hooi |
20.00-20.15 | Product Launching | |
20.15-21.30 | Dinner |
Day 1: 11th March, 2023 (Saturday) |
||
Time | Topic | Speaker |
08.00-08.20 | Registration | |
08.20-08.30 | Welcoming remarks | Tho Lye Mun |
Symposium 1: Challenges in lung cancer diagnosis and staging Chairperson: Arvindran Alaga/Andrea Ban Yu-Lin |
||
08.30-08.50 | Staging of lung cancer - Radiologist perspective | Zuhanis Abdul Hamid |
08.50-09.10 | Staging of lung cancer - Pulmonologist perspective | Hema Yamini Devi |
09.10-09.30 | Biomarkers testing in Malaysia? How to choose | Roziana Ariffin |
09.30-09.50 | NGS in lung cancer – choosing the right test | Aaron Tan (Singapore) |
09.50-10.30 | Industry Sponsored Tea Symposium: AstraZeneca Chairperson: Tho Lye Mun Complementing Trial Results with Real World Practice: A crossover from FLAURA to REIWA |
Tan Chih Kiang |
10.30-11.00 | Tea Break | |
Symposium 2: Early stage and locally invasive lung cancer Chairperson: Lim Yueh Ni/ Benedict Dharmaraj Retna Pandian |
||
11.00-11.20 | Contemporary management of early-stage lung cancer - a thoracic surgical perspective | Anand Sachithanandan |
11.20-11.40 | Approach to borderline operable NSCLC | Soon Sing Yang |
11.40-12.00 | SBRT in early lung cancer and oligo-metastasis | Jasmin Loh Pei Yuin |
12.00-13.00 | Industry Sponsored Lunch Symposium: Roche Chairperson: Liam Chong Kin Changing landscape in early stage Lung cancer with Immunotherapy: What’s new? |
Toh Chee Keong (Singapore) |
13.00-14.00 | Lunch Break | |
Symposium 3: Small cell lung cancer and other neuroendocrine tumour Chairperson: Ibtisam Muhamad Nor/ Azlina Shamsudin |
||
14.00-14.20 | New approaches in SCLC | Malwinder Singh Sandhu |
14.20-14.40 | Role of surgery in SCLC | Narasimman Sathiamurthy |
14.40-15.00 | Carcinoid and other lung neuroendocrine tumour: An update | Teo Yin Keong |
15.00-15.40 | Industry Sponsored Tea Symposium: Pfizer Chairperson: Liam Chong Kin Let’s tALK about the Evolving ALK+ NSCLC Treatment Landscape |
John Low Seng Hooi |
15.40-16.10 | Tea Break | |
Symposium 4: Advanced NSCLC without driver mutation Chairperson: John Low Seng Hooi/Syazatul Syakirin |
||
16.10-16.30 | Advanced NSCLC without driver mutation: Treatment Landscape in Malaysia | Nurhayati Mohd Marzuki |
16.30-16.50 | Best first line regime for advanced NSCLC without driver mutation | Ahn Myung Ju (Korea) |
16.50-17.10 | Best second line regime after chemotherapy and immunotherapy combination | Tan Jiunn Liang |
17.10-18.10 | Industry Sponsored Dinner Symposium: MSD Chairperson: Tan Jiunn Liang Deep Diving into the Emerging Evidence of ICI and chemotherapy for PDL-1 negative expression. |
Ahn Myung Ju (Korea) |
18.10-20.00 | Dinner |
Day 2: 12th March, 2023 (Sunday) |
||
Time | Topic | Speaker |
08.00-08.30 | Registration | |
Symposium 5: Targeted therapy in Advanced NSCLC Chairperson: Irfhan Hyder/Marfuah Nik Eezamuddeen |
||
08.30-08.50 | Real world EGFR and ALK data: Malaysian Lung Cancer Registry | Poh Mau Ern |
08.50-09.10 | New targets beyond EGFR, ALK and ROS1 | Liam Chong Kin |
09.10-09.30 | What Next? Options after Progression on EGFR TKIs | Azza Omar |
09.30-09.50 | Approaches to uncommon EGFR mutation | Cho Byoung Chul (Korea) |
09.50-10.30 | Industry Sponsored Tea symposium: Boehringer Ingelheim Chairperson: Yap Beng Khiong Optimizing sequential treatment outcomes in EGFR mutation-positive NSCLC Patients |
Muthukkumaran Thiagarajan |
10.30-11.00 | Tea | |
Symposium 6: Palliative Care and Management of Symptoms and Common Adverse Events Chairperson: Aisya Natasya Musa/Leong Siew Mooi |
||
11.00-11.20 | Palliative Radiotherapy in the Era of Targeted and Immunotherapy | Daniel Gan Eng Hwee |
11.20-11.40 | Management of life threatening irAE | Aaron Tan (Singapore) |
11.40-12.00 | Palliation in the era of so many treatment possibilities – how to know when to stop? | Richard Lim Boon Leong |
12.00-13.00 | Industry Sponsored Lunch Symposium: Takeda Chairperson: Ho Gwo Fuang Treatment selection of newly diagnosed ALK+ NSCLC with baseline brain metastases |
Min Hee Hong (Korea) |
13.00-14.00 | Lunch | |
14.00-15.30 | Multidisciplinary Discussion Chairperson: How Soon Hin / Tan Jiunn Liang |
Panelists: |
15.30-16.10 | Industry Sponsored Tea Symposium: Amgen Chairperson: Pang Yong Kek Unmet need in KRAS G12C |
Alfredo Addeo (Switzerland) |
16.10-16.30 | Closing remarks & lucky draw | How Soon Hin |
16.10-17.00 | Tea |